
Verrica Pharmaceuticals Inc.
97
Recent developments highlight Verrica's clinical progress, financial reporting, and commercial activities including Phase 3 trial dosing, earnings calls, and product launches.
- Verrica dosed the first U.S. and Japanese patients in the Phase 3 COVE-3 trial for YCANTH in common warts, marking a key clinical milestone [N5].
- The company reported a net loss for Q2 2026 but showed revenue growth, with detailed earnings call discussions on financial and operational performance [N2][N3][N4].
- Torii Pharmaceutical launched YCANTH in Japan for molluscum treatment in February 2026, expanding geographic commercialization [S1].
- Verrica continues to advance its sales and marketing initiatives targeting pediatric dermatologists, dermatologists, and pediatricians in the U.S. [N1].
Verrica Pharmaceuticals Inc. develops and commercializes dermatologic therapeutics, focusing on clinician-administered treatments for skin diseases with high unmet needs. Its commercial product, YCANTH (VP-102), is FDA-approved for molluscum contagiosum and launched in the U.S. in August 2023. The company is advancing YCANTH for common warts through a global Phase 3 clinical program and developing VP-315 for basal cell carcinoma with Phase 3 planning underway. Verrica has a collaboration with Torii Pharmaceutical for the Japanese market, where YCANTH is approved and launched. The company employs a specialized sales force targeting dermatologists and pediatricians and utilizes reimbursement strategies including a permanent J-code. Financially, Verrica reported $6.9 million revenue and a net loss of $12.4 million for Q3 2026, with liquidity supported by a credit agreement.
Verrica Pharmaceuticals Inc. is a dermatology-focused therapeutics company with a commercial FDA-approved product, YCANTH (VP-102), for molluscum contagiosum and ongoing development programs for common warts and basal cell carcinoma. The company has established a specialized U.S. sales force and achieved significant insurance coverage for YCANTH. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, Verrica reported $14.4 million in cash and equivalents, $6.9 million in revenue, and a net loss of $12.4 million for the quarter. The company has financing arrangements with covenants tied to YCANTH revenue and liquidity.
Verrica's commercial launch of YCANTH for molluscum contagiosum with established insurance coverage and a specialized sales force provides a foundation for revenue growth. The initiation of global Phase 3 trials for YCANTH in common warts and planning for VP-315 Phase 3 trials in basal cell carcinoma represent key clinical development milestones. Strategic partnerships, including with Torii Pharmaceutical in Japan, support geographic expansion and cost-sharing for clinical programs.
Verrica faces risks including ongoing net losses and the need to manage liquidity and debt covenants under its credit agreement. Clinical development programs carry inherent risks of trial outcomes and regulatory approvals. The company depends on successful commercialization efforts and insurance reimbursement to drive adoption. Competition in dermatologic therapeutics and potential challenges in manufacturing transfer and cost-sharing arrangements with partners may impact execution.
Verrica's moat is supported by its FDA-approved proprietary drug-device combination YCANTH (VP-102) with New Chemical Entity status granting regulatory exclusivity, a specialized sales organization targeting key healthcare providers, established insurance reimbursement coverage including a permanent J-code, and strategic partnerships such as the collaboration with Torii Pharmaceutical for the Japanese market. Its clinical pipeline with ongoing Phase 3 programs for common warts and basal cell carcinoma further strengthens its position in dermatologic therapeutics.
• Liquidity and Financing Risk: Verrica's ability to meet payment obligations under its PD Credit Agreement depends on maintaining sufficient cash reserves and revenue from YCANTH. Failure to comply with covenants could trigger default and acceleration of debt repayment, potentially harming operations [S2].
• Clinical Development Risk: The success of ongoing Phase 3 trials for YCANTH in common warts and planned Phase 3 trials for VP-315 in basal cell carcinoma is uncertain. Negative trial outcomes or regulatory delays could impact product approvals and commercialization.
• Commercial Execution Risk: The company’s revenue growth depends on effective sales and marketing efforts, insurance reimbursement, and physician adoption of YCANTH. Challenges in these areas could limit market penetration.
• Partnership and Manufacturing Risk: Verrica’s collaboration with Torii Pharmaceutical involves cost-sharing and manufacturing transfer arrangements. Delays or disputes could affect product supply and financial obligations.
Business trends: Continued clinical development of YCANTH for common warts and VP-315 for basal cell carcinoma, expansion of commercial footprint in the U.S. and Japan, and insurance coverage growth.
Execution milestones: Completion of Phase 3 trials dosing, regulatory submissions, and advancement of manufacturing transfer and partnership agreements.
Key risks: Clinical trial outcomes, liquidity and debt covenant compliance, commercial adoption challenges, and partnership execution risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Verrica Pharmaceuticals Inc. is a therapeutics company focused on developing and commercializing medications for dermatologic diseases including skin cancers [S1].
- The company’s commercial product is YCANTH (VP-102), approved by the FDA in July 2023 for treatment of molluscum contagiosum in patients aged two years and older [S1].
- YCANTH (VP-102) is a proprietary drug-device combination containing a GMP-controlled formulation of cantharidin administered via a single-use precision applicator [S1].
- Verrica has built a specialized U.S. sales organization of approximately 40 field sales representatives targeting pediatric dermatologists, dermatologists, pediatricians, and select primary care providers [S1].
- YCANTH (VP-102) is reimbursed under a permanent J-code (J7354) effective April 1, 2024, and has coverage for approximately 250 million lives in the U.S. through insurance payor decisions [S1].
- The company is developing YCANTH (VP-102) for a follow-on indication to treat common warts, with a global Phase 3 clinical program initiated in 2025 [S1].
- Verrica estimates the U.S. market for molluscum and common warts each to be over $1 billion, with millions of patients affected annually [S1].
- The company is developing VP-315 (ruxotemitide), an oncolytic peptide-based injectable therapy for basal cell carcinoma (BCC) and other dermatologic oncology indications, with Phase 3 program planning underway [S1].
- VP-315 showed favorable safety and efficacy in Phase 2 trials, including a 51% complete histologic clearance rate and 86% tumor size reduction in BCC patients [S1].
- Verrica has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for development and commercialization of cantharidin-containing products in Japan, including YCANTH (TO-208) approved for molluscum in Japan [S1].
- Torii launched YCANTH in Japan for molluscum treatment in February 2026 [S1].
- The company’s financial snapshot as of September 30, 2026, shows cash and equivalents of $14.4 million, current assets of $36.4 million, current liabilities of $21.9 million, a current ratio of 1.66, and a cash ratio of 0.66 [S2].
- For the quarter ended September 30, 2026, Verrica reported revenue of $6.9 million and a net loss of $12.4 million, with basic and diluted EPS of -$0.58 [S2].
- Verrica has a PD Credit Agreement providing up to $27.5 million in financing, with covenants including minimum annual YCANTH revenue and minimum liquidity of $5 million [S2].
- The company’s sales and marketing efforts include targeted HCP education, digital advertising, and consumer awareness campaigns to drive adoption of YCANTH [S1].
- Physicians obtain YCANTH through a 'white bag' service from specialty pharmacies or on a buy-and-bill basis through distribution partners; Verrica launched YCANTH-Rx, a non-dispensing pharmacy, in Q4 2025 to streamline provider experience [S1].
- Recent news highlights include dosing of first U.S. and Japanese patients in Phase 3 trial for YCANTH in common warts, Q2 2026 earnings call reporting a loss but revenue growth, and ongoing clinical development updates [N1][N2][N3][N4][N5].
Generated 2026-11-13
- N2
- N3
- S1 | 2026-03-11 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-08-19 | www.nasdaq.com | Verrica Pharma Gains: What Is The Buzz? | https://www.nasdaq.com/articles/verrica-pharma-gains-what-buzz
- N2 | 2026-08-14 | www.nasdaq.com | Verrica (VRCA) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/verrica-vrca-q2-2026-earnings-call-transcript
- N3 | 2026-08-07 | www.nasdaq.com | Verrica Pharmaceuticals Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/verrica-pharmaceuticals-q2-earnings-call-highlights
- N4 | 2026-08-06 | www.nasdaq.com | Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/verrica-pharmaceuticals-inc-vrca-reports-q2-loss-beats-revenue-estimates
- N5 | 2026-06-22 | www.nasdaq.com | Verrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts | https://www.nasdaq.com/articles/verrica-doses-first-us-and-japanese-patients-phase-3-cove-3-trial-ycanth-common-warts
- N6 | 2026-05-13 | www.nasdaq.com | Verrica (VRCA) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/verrica-vrca-q1-2026-earnings-transcript
- N7 | 2026-05-13 | www.nasdaq.com | Verrica Pharmaceuticals Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/verrica-pharmaceuticals-q1-earnings-call-highlights
- N8 | 2026-05-12 | www.nasdaq.com | Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/verrica-pharmaceuticals-inc-vrca-reports-q1-loss-tops-revenue-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


